Finance

Lists
A1RG34:BVMF
Argenx Se Bdr
187,38 BRL
+1,99%
(+3,65) 1D
6-окт., 16:56:00 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for A1RG34...
Open
187,38 BRL
High
187,38 BRL
Low
187,38 BRL
Mkt. cap
58,45 млд
Avg. vol.
57,00
Volume
0,00
52-wk high
213,15 BRL
52-wk low
143,22 BRL
Shares outstanding
62,56 млн
No. of employees
2 миң
Open
187,38 BRL
High
187,38 BRL
Low
187,38 BRL
Mkt. cap
58,45 млд
Avg. vol.
57,00
Volume
0,00
52-wk high
213,15 BRL
52-wk low
143,22 BRL
Shares outstanding
62,56 млн
No. of employees
2 миң
News stories
From web sources and news partners
Profile
Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs. Wikipedia
About Argenx Se Bdr
CEO-
Employees1,86 миң
Founded2008-ж., 25-апр.
Headquarters-
Sector-
Websiteargenx.com
Last report
2026-ж., 23-июл.
Fiscal period
Q2 2026
EPS / Est. (USD)
7,32 USD / 6,52 USD
+12,32%beat
Revenue / Est. (USD)
1,54 млд / 1,44 млд
+6,82%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
1,15 млд
1,31 млд
1,31 млд
1,54 млд
Cost of goods sold
465,08 млн
521,40 млн
564,00 млн
631,00 млн
Cost of revenue
465,08 млн
521,40 млн
564,00 млн
631,00 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
336,29 млн
429,62 млн
355,00 млн
417,00 млн
Operating expense
336,29 млн
429,62 млн
355,00 млн
417,00 млн
Total operating expenses
801,37 млн
951,02 млн
919,00 млн
1,05 млд
Operating income
349,97 млн
359,56 млн
394,00 млн
493,00 млн
Other non operating income
-
-907,00 миң
-
-1,00 млн
EBT including unusual items
386,05 млн
403,29 млн
426,00 млн
531,00 млн
EBT excluding unusual items
386,05 млн
391,71 млн
426,00 млн
531,00 млн
Income tax expense
41,80 млн
-129,66 млн
60,00 млн
59,00 млн
Effective tax rate
10,83%
-32,15%
14,08%
11,11%
Other operating expenses
-
-
-
-
Net income
344,26 млн
532,95 млн
366,00 млн
472,00 млн
Net profit margin
29,90%
40,67%
27,88%
30,63%
Earnings per share
5,18
8,02
5,52
7,32
Interest and investment income
42,70 млн
44,95 млн
44,00 млн
48,00 млн
Interest expense
-993,00 миң
-
-1,00 млн
-1,00 млн
Net interest expenses
41,71 млн
44,95 млн
43,00 млн
47,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
350,35 млн
361,38 млн
395,82 млн
501,50 млн
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору